COMMIT / NRG-GI004 / SWOG S1610 Trial

[Slide 1] ! COMMIT Trial - dMMR/MSI-H mCRC Is immunotherapy alone enough? @ DrRishabhOnco Study Design Key Results Safety Signal — PFS - Grade ≥3 AEs HR 0.44 (95% (123-0.84) ! Higher with Combination, 30.0 vs 4.3 Months as Expected with Chemo- therapy-Based Regimens - ORR - 80.6% vs 46% dMMR/MSI-H - 12-Month DCR - Metastatic Colorectal Cancer 0-0 First-Line Treatment 12 62.9% vs 32.4% mo Efficacy Toxicity Atezolizumab Monotherapy - Median Follow-Up: 3.5 Years - vs Chemo + VEGF IO VS + Expected with added chemo + VEGF blockade n = 102 (interim analysis) Phase III I NRG-GI004 / SWOG-S1610 IO Monotherapy May Not Be Sufficient for All dMMR/MSi-nCRC Adding Chemotherapy + VEGF Blockade Improves PFS and Disease Control, with Higher Toxicity

[Slide 1] NRG Progression-free Survival ONCOLOGY Advancing Research Improving Lines 1.0 HR 0.439; 95% CI 0.23-0.84; P =0.0103 0.8 Median PFS (months) 0.6 Survival Probability 24.5 (95% CI, 10.1-not estimable) 0.4 5.3 (95% CI, 2.2-18.2) 0.2 0.0 Atezo 40 12 9 6 5 5 1 FFX/bev/atezo 38 24 17 13 9 6 4 0 10 20 30 40 50 60 Months Atezo FFX/bev/atezo ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium --- [Slide 2] 1.0 There was no difference 0.8 in os between the arms: HR of 1.04 0.6 (95% CI, 0.47-2.28, P Survival Probability = 0.90) 0.4 24-month OS: 0.2 FFX/bev/atezo: 67% Atezo: 67% 0.0 Atezo 41 29 22 18 14 11 5 FFX/bev/atezo 41 30 24 20 14 11 8 0 10 20 30 40 50 60 Months Atezo FFX/bev/atezo

[Slide 1] NRG Progression-free Survival ONCOLOGY febencing Branch depending - 1.0 HR 0.439; 95% CI 0.23-0.84; P =0.0103 0.8 Median PFS (months) 0.6 Survival Probability 24.5 (95% CI, 10.1-not estimable) 0.4 5.3 (95% CI, 2.2-18.2) 0.2 0.0 Atezo 40 12 9 6 5 5 1 FFX/bev/atezo 38 24 17 13 9 6 4 0 10 20 30 40 50 60 Months Atezo FFX/beviatezo ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium This presentation is the intellectual property of the author Contact Dr. Rocha Lima at crochali Pwakehealth edu for permission to reprint and/or distribute --- [Slide 2] NRG Progression-free Survival ONCOLOGY febencing Branch depending - 1.0 HR 0.439; 95% CI 0.23-0.84; P =0.0103 0.8 Median PFS (months) 0.6 Survival Probability 24.5 (95% CI, 10.1-not estimable) 0.4 5.3 (95% CI, 2.2-18.2) 0.2 0.0 Atezo 40 12 9 6 5 5 1 FFX/bev/atezo 38 24 17 13 9 6 4 0 10 20 30 40 50 60 Months Atezo FFX/beviatezo ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium This presentation is the intellectual property of the author Contact Dr. Rocha Lima at crochali Pwakehealth edu for permission to reprint and/or distribute --- [Slide 3] NRG Overall Survival ONCOLOGY Branch depending - 1.0 There was no difference 0.8 in OS between the arms: HR of 1.04 0.6 (95% CI, 0.47-2.28, P Survival Probability = 0.90) 0.4 . 24-month OS: 0.2 FFX/bev/atezo: 67% Atezo: 67% 0.0 Atezo 41 29 22 18 14 11 5 FFX/bev/atezo 41 30 24 20 14 11 8 0 10 20 30 40 50 60 Months Atezo FFX/bev/atezo ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium This presentation is the intellectual property of the author Contact Dr. Rocha Lima at trochali Pwakehealth edu for permission to reprint and/or distribute --- [Slide 4] NRG Additional Efficacy Outcomes ONCOLOGY Breanch depending - Efficacy Outcome FFX/bev/atezo Atezo Progression-free Survival 12 months 66.7% 35.1% 24 months 53.7% 31.6% Overall Response Rate 86.1% 46% Response Status CR 36.1% 18.9% PR 50% 27% SD 11.1% 21.6% PD 2.8% 32.4% Disease Control Rate 12 months 64.7% 32.4% ASCO Gastrointestinal Jan 8-10,2026 Cancers Symposium This presentation is the intellectual property of the author Contact Dr. Mocha Lima at prochale wakehealth edu for permission to reprint and/or distribute

[Slide 1] NRG Study Design ONCOLOGY Marring Improving Check FFX/Bevacizumab FFX/bevacizumab dMMR/MSI-H mCRC without prior systemic R + treatment for metastatic disease* Atezolizumab+ Randomization 1:1:1 (then 1:1) Stratified according to: Atezolizumab* BRAF mutation (V600E; non-V600E, WT, or Unknown) Metastatic disease: (liver-only; extra-hepatic) Prior adjuvant therapy for CRC * One cycle of FOLFOX or CAPOX with or without bev (or biosimilar) allowed prior to enrollment t FFX/bev/atezo: oxaliplatin 85 mg/m2 IV + leucovorin 400 mg/m2 IV + bevacizumab 5 mg/kg IV+ 5-FU 400 mg/m2 IV bolus on Day 1 followed by 5-FU 2400 mg/m2 IV over 46 hours plus atezo (840mg IV q2wks) # Atezo monotherapy: 840mg IV q2wks ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium This presentation is the intellectual property of the author. Contact Dr. Rocha Lima at crochali wakehealth edu for permission to reprint and/or distribute. --- [Slide 2] NRG Progression-free Survival ONCOLOGY belowing Frown - 1.0 HR 0.439; 95% CI 0.23-0.84; P =0.0103 0.8 Median PFS (months) 0.6 Survival Probability 24.5 (95% CI, 10.1-not estimable) 0.4 5.3 (95% CI, 2.2-18.2) 0.2 0.0 Atezo 40 12 9 6 5 5 1 FFX/bev/atezo 38 24 17 13 9 6 4 0 10 20 30 40 50 60 Months Atezo FFX/bev/atezo ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium This presentation is the intellectual property of the author. Contact Dr. Rocha Lima at crochali wakehealth edu for permission to reprint and/or distribute. --- [Slide 3] NRG Additional Efficacy Outcomes ONCOLOGY Branch Improving - Efficacy Outcome FFX/bev/atezo Atezo Progression-free Survival 12 months 66.7% 35.1% 24 months 53.7% 31.6% Overall Response Rate 86.1% 46% Response Status CR 36.1% 18.9% PR 50% 27% SD 11.1% 21.6% PD 2.8% 32.4% Disease Control Rate 12 months 64.7% 32.4% ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium This presentation is the intellectual property of the author. Contact Dr. Rocha Lima at crochali wakehealth edu for permission to reprint and/or distribute. --- [Slide 4] NRG Conclusions ONCOLOGY Advancing boards Importing - The combination of FFX/bev/atezo demonstrated a statistically significant improvement in PFS compared to atezo monotherapy in the first-line setting for dMMR/MSI-H mCRC HR 0.439; 95% CI 0.23-0.84, P=0.0103 FFX/bev/atezo resulted in improved complete responses and reduced progressive disease compared to atezo monotherapy Complete response: 36.1% vs 18.9% Progressive disease: 2.8% vs 32.4% Higher rates of G3-4 diarrhea, neutropenia, hypertension, and infection observed in the FFX/bev/atezo arm Future efforts are needed to characterize the subsets of dMMR/MSI-H CRC that require intensification of therapy beyond single-agent PD-1/PD-L1 therapy. Ongoing correlative analyses will hopefully provide deeper mechanistic interpretation of the differential outcomes across treatment arms. ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium This presentation is the intellectual property of the author. Contact Dr. Rocha Lima at crochali wakehealth edu for permission to reprint and/or distribute.

[Slide 1] ASCO GI 2026 Abstract 14 COMMIT Trial M Triple Combo in dMMR/MSI-H Colorectal Cancer Adding Chemo + Bevacizumab to Atezolizumab dramatically improves PFS compared to Atezolizumab alone. 1 THE "MONOTHERAPY GAP" WHY THIS TRIAL? Single-agent checkpoint inhibitors (like Pembrolizumab in KEYNOTE-177) are THE COMMIT STRATEGY standard but still leave room for improvement + + Atezolizumab Bevacizumab FOLFOX Superiority? Objective: Boost Efficacy with Combo 2 PHASE 3 DESIGN (TREE VIEW) Experimental ARM A Atezo + Bev FOLFOX PATIENT POPULATION Checkpoint Inhibitor Anti-VEGF Chemotherapy Previously Untreated Metastatic CRC Control ARM B dMMR MSI-H Only Atezolizumab Mono Single Agent Immunotherapy stopped early due CheckMate results arm) PROGRESSION-FREE SURVIVAL 4 RESPONSE & SAFETY 3 (PFS) HR 0.44 (Huge Benefit) OBJECTIVE RESPONSE RATE MEDIAN PFS Combo Arm $6.1% 24.5 Mo Mono Arm 46.0% SAFETY TRADE-OFF 5.3 Mo Grade 3-5 AEs (Combo) 83% Grade 3-5 AEs (Mono) 44% Combination Arm Atezolizumab Mono *More toxicity with more drugs. CLINICAL TAKEAWAY The COMMIT trial establishes FOLFOX Bevacizumab Atezolizumab as a highly active option for dMMR/MSI H mCRC, significantly outperforming single-agent Atezolizumab However, this comes at the cost of higher toxicity. SOURCE REFERENCE Rocha Lima CMSP, et al. "Combination Chemotherapy, Bevactzumab, Atezolizumab Prof. Dr. Mustafa Ozdogan Prolongs PFS... in dMMR/MSI-H mCRC". STANBUL MEMORIAL GOZTEPE CANCER CENTER Presented at: 2026 ASCO Gastrointestinal Cancers Symposium. Abstract 14. --- [Slide 2] NRG Progression-free Survival ONCOLOGY Advancing Amount Impouning Line 1.0 HR 0.439; 95% CI 0.23-0.84; P =0.0103 0.8 Median PFS (months) 0.6 Survival Probability 24.5 (95% CI, 10.1-not estimable) 0.4 5.3 (95% CI, 2.2-18.2) 0.2 0.0 Atezo 40 12 9 6 5 5 1 FFX/bev/atezo 38 24 17 13 9 6 4 0 10 20 30 40 50 60 Months Atezo FFX/bev/atezo ASCO Gastrointestinal Jan 8-10, 2026 Cancers Symposium